Key Takeaways
- • ARK Invest sold approximately $72 million in Advanced Micro Devices (AMD) shares across multiple funds, extending a pattern of reduced semiconductor exposure and locking in gains from the chipmaker's strong performance.
- • Cathie Wood's funds significantly increased exposure to artificial intelligence infrastructure and digital advertising, adding over 124,000 Alphabet shares and approximately 47,000 Meta shares across multiple ETFs.
- • ARK deployed capital into Intellia Therapeutics, purchasing 3.41 million shares valued at over $43 million, and established a new position in CoreWeave by acquiring 162,000 shares through ARKK and ARKW.
- • The portfolio rotation signals a strategic shift away from semiconductor cyclicality toward large-cap technology names with clearer AI monetization pathways and established digital advertising platforms.
- • Concurrent with equity moves, ARK trimmed exposure to bitcoin exchange-traded funds and made smaller cuts across other holdings, indicating a recalibration of risk positioning.
Summary
ARK Invest, the activist investment firm led by Cathie Wood, executed a significant portfolio rotation in early May 2026, selling approximately $72 million in Advanced Micro Devices stock while simultaneously increasing positions in major technology names and AI-focused companies. The trades reflect a deliberate reallocation of capital from semiconductor exposure toward companies positioned to benefit from artificial intelligence infrastructure buildout and digital advertising growth.
The most substantial new deployment came through Intellia Therapeutics, where ARK added approximately 3.41 million shares valued at over $43 million across its ARKG and ARKK funds. Additionally, the firm established a fresh position in CoreWeave, a specialized infrastructure provider, acquiring 162,000 shares through ARKK and ARKW. These moves underscore Wood's confidence in companies operating at the intersection of AI hardware requirements and specialized compute infrastructure.
On the large-cap technology front, ARK increased its Alphabet position by more than 124,000 shares across several funds while adding approximately 47,000 shares of Meta Platforms. These additions position the firm to capitalize on both companies' expanding AI capabilities and their dominance in digital advertising, where AI-driven optimization is reshaping competitive dynamics.
The AMD reduction, while substantial in dollar terms, continues a recent trend rather than signaling an abrupt strategic reversal. By trimming semiconductor exposure after the stock's strong performance, ARK appears to be executing a disciplined profit-taking strategy while rebalancing risk. The concurrent reduction in bitcoin exchange-traded fund holdings and smaller cuts elsewhere suggest a broader portfolio optimization aimed at concentrating capital in higher-conviction technology and biotech positions with clearer long-term growth trajectories tied to AI adoption.
The most substantial new deployment came through Intellia Therapeutics, where ARK added approximately 3.41 million shares valued at over $43 million across its ARKG and ARKK funds. Additionally, the firm established a fresh position in CoreWeave, a specialized infrastructure provider, acquiring 162,000 shares through ARKK and ARKW. These moves underscore Wood's confidence in companies operating at the intersection of AI hardware requirements and specialized compute infrastructure.
On the large-cap technology front, ARK increased its Alphabet position by more than 124,000 shares across several funds while adding approximately 47,000 shares of Meta Platforms. These additions position the firm to capitalize on both companies' expanding AI capabilities and their dominance in digital advertising, where AI-driven optimization is reshaping competitive dynamics.
The AMD reduction, while substantial in dollar terms, continues a recent trend rather than signaling an abrupt strategic reversal. By trimming semiconductor exposure after the stock's strong performance, ARK appears to be executing a disciplined profit-taking strategy while rebalancing risk. The concurrent reduction in bitcoin exchange-traded fund holdings and smaller cuts elsewhere suggest a broader portfolio optimization aimed at concentrating capital in higher-conviction technology and biotech positions with clearer long-term growth trajectories tied to AI adoption.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.